The Cigna Group stock: Q3 growth lifts 2026 earnings outlook

The Cigna Group reported stronger third-quarter operating performance on Thursday, November 5, 2026, and lifted its full-year adjusted earnings outlook. The release, carried by Morningstar and PR Newswire, showed total revenue of 73.683 billion US dollars for the three months ended September 30, up 6 percent from 69.748 billion US dollars a year earlier.

Shareholders' net income fell to 1.442 billion US dollars, or 5.47 US dollars per share, from 1.868 billion US dollars, or 6.98 US dollars per share, in the prior-year quarter. The decline mainly reflected the absence of an after-tax gain on a sale recognized in the third quarter of 2025. On the company's adjusted measure, income from operations reached 2.104 billion US dollars, or 7.98 US dollars per share, compared with 2.096 billion US dollars, or 7.83 US dollars per share, a year earlier.

Healthcare segment drives earnings upgrade

Cigna Healthcare was the main operating bright spot. Adjusted revenue in the segment rose 9 percent to 11.708 billion US dollars, while pretax adjusted income from operations increased 15 percent to 1.193 billion US dollars. The company attributed the improvement primarily to higher net investment income and better operating efficiency.

Evernorth Health Services generated adjusted revenue of 63.774 billion US dollars, an increase of 6 percent. Pretax adjusted income from operations declined 4 percent to 1.829 billion US dollars as lower Pharmacy Benefit Services earnings offset growth in Specialty and Care Services. Pharmacy Benefit Services revenue increased 9 percent, but its pretax adjusted operating income fell 22 percent amid large client contract renewals and strategic investments. Specialty and Care Services posted 15 percent earnings growth.

The Cigna Group raised its 2026 consolidated adjusted income from operations outlook by 0.15 US dollars per share to at least 30.60 US dollars. The company also increased its Cigna Healthcare pretax adjusted earnings target by 50 million US dollars to at least 4.600 billion US dollars, while maintaining Evernorth's target of at least 6.900 billion US dollars. The expected Cigna Healthcare medical care ratio midpoint remains 84.2 percent, but the range was narrowed to plus or minus 25 basis points.

Capital returns and customer trends

The company repurchased 1.8 million shares for approximately 500 million US dollars through November 4. Total customer relationships stood at 177.562 million at September 30, down 6 percent from year-end 2025. Pharmacy and behavioral customers declined, while total medical customers rose 2 percent to 18.452 million.

The real-time quote of The Cigna Group stock traded at 264.30 euros on Lang & Schwarz at 13:46 CET on Monday, November 9, 0.13 percent below the Xetra close of Friday, November 6. The comparison puts the current European listing in a mildly weaker position ahead of the next U.S. session, without establishing a direct link to the earnings release.

For investors, the raised outlook supports the view that Cigna Healthcare's earnings momentum is offsetting pressure in parts of Evernorth. The lower reported net income also underlines why management emphasizes adjusted operating earnings, which exclude investment results, acquired-intangible amortization and special items.

The broader US market environment remains relevant through the S&P 500, where changes in healthcare sentiment and interest-rate expectations can influence large managed-care stocks.

Further updates will depend on the company's execution against the tighter medical care ratio range, the development of Pharmacy Benefit Services and the delivery of its 2026 earnings target. More news and analyses on The Cigna Group stock are available in the company topic.